| 张慧 张苗 王佳林 宋洁 时牛.美沙拉嗪联合丹参酮胶囊对活动期溃疡性结肠炎疗效分析[J].,2015,15(34):6704-6707 |
| 美沙拉嗪联合丹参酮胶囊对活动期溃疡性结肠炎疗效分析 |
| The Curative Effect of Mesalazine Combined with Tanshinone Capsule onPatients with Active Ulcerative Colitis |
| |
| DOI： |
| 中文关键词: 丹参酮 美沙拉嗪 溃疡性结肠炎 |
| 英文关键词: Tanshinone Mesalazine Ulcerative colitis |
| 基金项目:内蒙古自治区卫生和计划生育委员会医疗卫生科研计划项目（201301007） |
|
| 摘要点击次数: 731 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨美沙拉嗪联合丹参酮胶囊对活动期溃疡性结肠炎患者血浆D-二聚体、CRP、凝血功能的影响及临床疗效。方法：
将90 例活动期溃疡性结肠炎患者按照随机数字表随机分为Ⅰ组、Ⅱ组及Ⅲ组，每组30 例，Ⅰ组给予口服柳氮磺胺吡啶肠溶片治
疗，Ⅱ组给予口服美沙拉嗪肠溶片治疗，Ⅲ组给予口服美沙拉嗪肠溶片+ 丹参酮胶囊治疗，三组均治疗4 周；检测各组患者治疗
前后凝血功能指标如活化部分凝血酶原时间(APTT)、纤维蛋白原(FIB)、血小板计数(PLT)、血小板平均体积(MPV)、血小板最大聚
集率[PAG(Max)]和D -二聚体(D-D)、C- 反应蛋白(CRP)，Mayo 疾病活动指数评分；比较三组之间的差异。结果：与Ⅰ及Ⅱ组比
较，Ⅲ组PLT、PAG(Max)及D-D 在治疗2、4 周后明显降低(P＜0.05)，APTT 及MPV 在治疗4 周后升高(P＜0.05)；FIB 及CRP 亦
在治疗4 周后降低(P＜0.05)；三组治疗后Mayo 指数评分均降低，但Ⅲ组治疗4 周后显著低于Ⅰ及Ⅱ组(P＜0.05)，其中Ⅲ组治疗
后Mayo 指数评分降低幅度(△Mayo 指数评分)大于Ⅰ及Ⅱ组(P＜0.05)。结论：美沙拉嗪联合丹参酮胶囊能够显著改善活动性溃
疡性结肠炎患者的炎症及高凝状态，在改善患者的临床症状方面优于单一用药。 |
| 英文摘要: |
| Objective:To investigate the effect of mesalazine combined with tanshinone capsule on plasma D-dimer, CRP and
coagulation function of patients with active ulcerative colitis and its clinical curative effect.Methods:Ninety patients with active
ulcerative colitis were divided according to random number table into three groups: groupⅠ, group Ⅱ and group Ⅲ , 30 cases in each
group. GroupⅠ was given oral Salazosulfapyridine enteric-coated tablets, group Ⅱ was given oral mesalazine enteric-coated tablets, and
group Ⅲ was given oral mesalazine enteric-coated tablets plus tanshinone capsule, all for 4 weeks. Detect the coagulation function
indexes before and after treatment such as activated partial prothrombin time (APTT), fibrinogen (FIB), platelet count (PLT), average
blood platelet volume (MPV), platelet maximum aggregation rate [PAG (Max)] and D dimer (D - D), C-reactive protein (CRP) and Mayo
disease activity score of the three groups. Compare the difference between three groups.Results:Compared with groupⅠ and Ⅱ , the
PLT, PAG (Max) and D - D Ⅲ group decreased significantly at 2, 4 weeks after treatment (P<0.05); APTT and MPV increased at 4
weeks after treatment (P < 0.05); FIB and CRP decreased at 4 weeks after treatment (P<0.05). Mayo index score of three groups all
decreased after treatment, but the score of group Ⅲ was significantly lower than that of groupⅠ and Ⅱ at 4 weeks after treatment (P <
0.05).Conclusion:The treatment of mesalazine enteric-coated tablets plus tanshinone capsules could significantly improve the
inflammation and high coagulation state in patients with active ulcerative colitis, and is superior to a single drug in improving the clinical
symptoms. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
